316 related articles for article (PubMed ID: 12881704)
21. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis.
Kondo S; Barna BP; Kondo Y; Tanaka Y; Casey G; Liu J; Morimura T; Kaakaji R; Peterson JW; Werbel B; Barnett GH
Oncogene; 1996 Sep; 13(6):1279-85. PubMed ID: 8808702
[TBL] [Abstract][Full Text] [Related]
22. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
Venot C; Maratrat M; Dureuil C; Conseiller E; Bracco L; Debussche L
EMBO J; 1998 Aug; 17(16):4668-79. PubMed ID: 9707426
[TBL] [Abstract][Full Text] [Related]
23. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint.
Saintigny Y; Rouillard D; Chaput B; Soussi T; Lopez BS
Oncogene; 1999 Jun; 18(24):3553-63. PubMed ID: 10380877
[TBL] [Abstract][Full Text] [Related]
25. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
26. Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
Wang YJ; Jeng JH; Chen RJ; Tseng H; Chen LC; Liang YC; Lin CH; Chen CH; Chu JS; Ho WL; Ho YS
Mol Carcinog; 2002 Aug; 34(4):199-210. PubMed ID: 12203371
[TBL] [Abstract][Full Text] [Related]
27. Induction of Mdm2 and enhancement of cell survival by bFGF.
Shaulian E; Resnitzky D; Shifman O; Blandino G; Amsterdam A; Yayon A; Oren M
Oncogene; 1997 Nov; 15(22):2717-25. PubMed ID: 9400998
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Arriola EL; Lopez AR; Chresta CM
Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
31. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
32. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.
Hastak K; Gupta S; Ahmad N; Agarwal MK; Agarwal ML; Mukhtar H
Oncogene; 2003 Jul; 22(31):4851-9. PubMed ID: 12894226
[TBL] [Abstract][Full Text] [Related]
33. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences.
Shimada A; Kato S; Enjo K; Osada M; Ikawa Y; Kohno K; Obinata M; Kanamaru R; Ikawa S; Ishioka C
Cancer Res; 1999 Jun; 59(12):2781-6. PubMed ID: 10383130
[TBL] [Abstract][Full Text] [Related]
34. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
35. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.
Luo JL; Yang Q; Tong WM; Hergenhahn M; Wang ZQ; Hollstein M
Oncogene; 2001 Jan; 20(3):320-8. PubMed ID: 11313961
[TBL] [Abstract][Full Text] [Related]
36. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells.
Kuo YC; Kuo PL; Hsu YL; Cho CY; Lin CC
Life Sci; 2006 Apr; 78(22):2550-7. PubMed ID: 16337242
[TBL] [Abstract][Full Text] [Related]
37. Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation.
Lu X; Burbidge SA; Griffin S; Smith HM
Oncogene; 1996 Jul; 13(2):413-8. PubMed ID: 8710381
[TBL] [Abstract][Full Text] [Related]
38. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
39. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.
Sharma K; Patel YC; Srikant CB
Mol Endocrinol; 1996 Dec; 10(12):1688-96. PubMed ID: 8961277
[TBL] [Abstract][Full Text] [Related]
40. Epstein-barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally.
Lin CS; Kuo HH; Chen JY; Yang CS; Wang WB
J Mol Biol; 2000 Oct; 303(1):7-23. PubMed ID: 11021966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
